Aethlon Medical shareholders to own about 95.25% post-merger
Aethlon Medical says pre-merger North Immunology stockholders (including investors participating in the private placement) are expected to own about 95.25% of the combined company.
Site Search
Search market news
Find public news by keyword, exact ticker, category and date.
Matching instruments
Open a ticker page for its news coverage. The news search below stays a text search.